Difference between revisions of "Team:CKWA-China"
Dragon210331 (Talk | contribs) |
Dragon210331 (Talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 32: | Line 32: | ||
data-y="['middle','middle','middle','middle']" | data-y="['middle','middle','middle','middle']" | ||
data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | ||
| − | <h4>LonEase</h4> | + | <h4>LonEase--a Natural Protease</h4> |
</div> | </div> | ||
| Line 42: | Line 42: | ||
data-y="['middle','middle','middle','middle']" | data-y="['middle','middle','middle','middle']" | ||
data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | ||
| − | <h2>Suppress Cancer </h2> | + | <h2>Suppress Cancer Recurrence </h2> |
</div> | </div> | ||
Latest revision as of 07:57, 21 October 2021
-
LonEase--a Natural Protease
Suppress Cancer Recurrence
2021iGEM ,CWKA-China is coming.
LonEase
Recurrence of cancer after surgical treatment is a major problem facing mankind nowadays, and cancer recurrence is a great threat for cancer patients. For example, bladder cancer recurs in up to 24%-84% of patients 5 years after surgical resection, in which overexpression of C-MYC protein is associated with approximately 44%-69% of these cases. We have investigated that Lon protein from uropathogenic Escherichia coli (UPEC) can be effective enough to degrade C-MYC protein and thus inhibit the proliferation of cancer cells. We plan to produce highly active Lon protease from E. coli this year and use it to design a drug to improve the surgical prognosis of bladder cancer population with C-myc gene overexpression.